Liver Disease Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global liver disease treatment market size is likely to be valued at US$ 28.5 billion in 2026 and is estimated to reach US$ 52.8 billion by 2033, growing at a CAGR of 9.2% during the forecast period 2026 to 2033, driven by the rising burden of fatty liver disease, the first approved therapies for metabolic dysfunction-associated steatohepatitis (MASH), and wide hepatitis treatment programs. A strong late-stage pipeline and active dealmaking are further shaping the market.

Driver- Rising MASH Burden and First Approved Drugs to Boost Treatment Demand

MASH is a form of fatty liver disease in which excess fat causes inflammation and scarring. It is closely linked to obesity and type 2 diabetes. It can progress to cirrhosis, liver failure, and liver cancer. For years, patients had no approved drug. That has now changed. Madrigal's Rezdiffra (resmetirom) was approved by the U.S. Food and Drug Administration (FDA) in March 2024. The European Commission followed with a conditional approval in August 2025.

Uptake has been fast. Rezdiffra net sales were US$958.4 million in 2025, up from US$180.1 million in 2024. In the second quarter of 2026, sales were US$364.3 million, up 71% year over year. More than 49,000 patients were on therapy as of June 30, 2026. Novo Nordisk's Wegovy (semaglutide) also won FDA approval for MASH in August 2025. These launches are building a treatment market from a near-zero base. Rezdiffra is a daily pill that targets the liver directly, while Wegovy works through GLP-1 receptor activity. Having two routes gives doctors more choice.

Large Viral Hepatitis Burden and Elimination Goals to Support Steady Demand

Viral hepatitis remains a major cause of liver disease. The WHO's 2026 Global Hepatitis Report states that hepatitis B and C caused 1.34 million deaths in 2024. Of these, 1.1 million were from hepatitis B and 240,000 from hepatitis C. About 1.8 million new infections occur each year. Hepatitis B and C account for 95% of hepatitis-related deaths.

Treatment gaps leave large room for growth. Fewer than 5% of people with chronic hepatitis B receive treatment. Only 20% of people with hepatitis C have been treated since 2015. The WHO says current progress is not enough to meet all 2030 elimination targets. Governments are therefore expanding testing and treatment. This keeps demand for antivirals steady over the forecast period. Hepatitis B prevalence among children under five fell to 0.6%, and 85 countries reached the 2030 target of 0.1% or better. Yet the WHO African Region had 68% of new hepatitis B infections, and only 17% of newborns there received the birth-dose vaccine.

Restraint- High Drug Costs and Reimbursement Hurdles May Restrict Access

New liver drugs are costly, and payers are cautious. In March 2026, Germany's Federal Joint Committee (G-BA) ruled that an additional benefit of Rezdiffra is not proven. It estimated 15,000 to 24,000 eligible patients. The annual cost was €32,205.38 (approx. US$36,052) per patient after statutory rebates. The decision is valid until October 1, 2029.

England has also raised concerns. In June 2026, the National Institute for Health and Care Excellence (NICE) issued draft guidance that did not recommend resmetirom for adults with F2 to F3 MASH. The committee noted cost-effectiveness estimates of £35,034 (around US$46,996) and £57,755 (approx. US$77,476) per quality-adjusted life year. It said the most plausible threshold was £25,000 (nearly US$33,536). It also cited only one year of trial follow-up. The draft may change after consultation. Payers also want long-term outcomes data. Month 54 trial data are expected only in 2028, according to NICE. Under-diagnosis adds to the problem, since MASH often shows no symptoms until it is advanced. Hepatitis treatment faces another barrier. People who inject drugs account for 44% of new hepatitis C infections, and they are often hard to reach with testing and care.

Opportunity- Late-stage MASH Pipeline and Combination Therapies to Fuel Growth

Large drugmakers are buying into the space. In October 2025, Novo Nordisk agreed to acquire Akero Therapeutics for $54 per share, about US$4.7 billion upfront. Akero shareholders could receive a further $6 per share if U.S. regulators approve efruxifermin. It was the third MASH acquisition since May 2025. Roche acquired 89bio, and GSK bought a prospect from Boston Pharmaceuticals.

Madrigal is also expanding. A Phase 3 outcomes trial of Rezdiffra in compensated MASH cirrhosis is ongoing. In June 2026, it started Phase 1 dosing of MGL-2086, an oral GLP-1, as part of a combination program. Three new resmetirom patents were also issued. Madrigal's CEO has said that the label requires no biopsy to qualify for treatment, which can ease prescribing. Combination therapies and new targets could widen the treated population beyond early fibrosis.

Hepatitis B Functional Cure Advances to Open Opportunities in Asia Pacific

A new class of hepatitis B therapies is emerging. In October 2025, China's National Medical Products Administration approved Pegbing, made by Amoytop Biotech. It is used with antiviral medication to clear the hepatitis B surface antigen in adults with chronic hepatitis B. A Chinese foundation called it the world's first market authorization for a functional cure drug. In the trial, 31.4% of patients on combination therapy achieved clinical cure 24 weeks after stopping all medications.

The need is large. China has about 75 million chronic hepatitis B patients. More than 92% of liver cancer cases in China are linked to hepatitis B. Liver cancer incidence was about 10.7% among treated patients and nearly 15% among untreated patients. It fell to about 1% among those who achieved clinical cure. GSK's bepirovirsen has also been accepted for regulatory review in China. Such therapies can shift care from lifelong suppression toward finite treatment.

Disease Type Insights

Viral hepatitis is predicted to lead with a share of about 41.8% in 2026, because hepatitis B and C affect about 287 million people worldwide. Many patients need lifelong therapy for hepatitis B. Hepatitis C patients receive short, curative courses. Public programs and generic access support volumes, especially in Asia and Africa.

MASH is estimated to be the fastest-growing segment in the forecast period, as new drugs are launching and screening is improving. Madrigal estimates that about 370,000 people in Europe have been diagnosed with MASH with moderate to advanced fibrosis. Liver cancer is expected to remain in the second position in 2026, since it needs costly targeted and immune therapies. Others include cirrhosis complications and autoimmune liver diseases. The WHO notes that ten countries account for 69% of hepatitis B deaths, so country-level programs matter.

Treatment Type Insights

Antivirals are anticipated to dominate with a share of around 38.7% in 2026, because they are the base of care for hepatitis B and C. They are used by large patient groups for long periods. Hepatitis C drugs can cure most patients in weeks. Hepatitis B drugs suppress the virus and lower the risk of cirrhosis and cancer. Steady demand keeps this segment in the lead. Resmetirom, by comparison, activates a thyroid hormone receptor in the liver to reduce fat. In the pivotal trial, about 26% to 30% of patients on the drug achieved MASH resolution without worsening fibrosis, compared with 10% on placebo.

Metabolic and antifibrotic therapies are expected to be the fastest-growing segment in the forecast period, as resmetirom, semaglutide, and FGF21 candidates move into wider use. Oncology therapies are likely to remain in the second position in 2026. Others include supportive care, transplant drugs, and treatments for rare liver conditions.

North America Liver Disease Treatment Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 40.2%, supported by early access to new MASH drugs, strong hepatology networks, and high treatment spending. Madrigal's U.S. sales and patient numbers show quick uptake. Rising obesity and diabetes rates add to the patient pool. However, high prices and insurance hurdles remain challenges. Madrigal also launched its MASH Across America awareness campaign in Philadelphia.

U.S. Liver Disease Treatment Market Trends

A share of nearly 81.3% is expected to be held by the U.S. in 2026 in North America, because the country was first to approve both Rezdiffra and Wegovy for MASH. Rezdiffra's 2025 sales reached US$958.4 million. Madrigal reported more than 36,250 patients on therapy by the end of 2025. It later passed 50,000 in early July 2026. Meanwhile, drugmakers are competing through acquisitions and late-stage trials. Hence, the U.S. sets the pace for pricing and launch trends.

Asia Pacific Liver Disease Treatment Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 26.8%, because of a large pool of hepatitis B patients, rising fatty liver rates, and new drug approvals. Regulators in China and India have approved new therapies in the past year. Screening drives are also widening. However, low treatment rates and cost limits remain challenges.

China Liver Disease Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 39.6%, supported by about 75 million chronic hepatitis B patients and strong domestic drug development. Pegbing was approved in October 2025 for use with antivirals to clear the hepatitis B surface antigen. GSK's bepirovirsen was accepted for review in China. More than 92% of liver cancer cases in China are linked to hepatitis B. Hence, antiviral and cancer prevention efforts remain a priority.

India Liver Disease Treatment Market Trends

India is expected to be the fastest-growing in Asia Pacific in the forecast period with a share of nearly 11.8% in 2026, backed by a large fatty liver population and rising use of obesity drugs. In July 2026, India's drug regulator approved Wegovy for noncirrhotic MASH with moderate to advanced fibrosis. Novo Nordisk India states that two in three Indians have fatty liver disease. That is a company claim.

Europe Liver Disease Treatment Market Trends

Europe will likely see decent growth in the forecast period with a share of roughly 14.6% in 2026 globally, as new MASH drugs reach patients but payers review costs closely. Hence, growth is more gradual than in North America. The European Commission approved Rezdiffra in August 2025. It is the first targeted therapy in Europe for MASH with moderate to advanced fibrosis. Madrigal plans a country-by-country rollout.

Germany Liver Disease Treatment Market Trends

A share of nearly 24.7% is predicted to be held by Germany in 2026 in Europe, backed by an early launch, strong hospital networks, and wide insurance cover. Madrigal launched Rezdiffra in Germany in September 2025. In March 2026, the G-BA found that an additional benefit was not proven. It estimated 15,000 to 24,000 eligible patients. Price talks and real-world data will shape future uptake. Insurers will watch the annual therapy cost of about €32,205 closely.

U.K. Liver Disease Treatment Market Trends

A share of roughly 17.9% is expected to be held by the U.K. in 2026 in Europe, because of a large NHS patient base and rising fatty liver cases. The Medicines and Healthcare products Regulatory Agency (MHRA) approved Rezdiffra in June 2026. It approved Wegovy for MASH about a month later. Neither is yet routinely available on the NHS. NICE draft guidance did not recommend resmetirom, so access depends on the final decision. NICE says MASH is likely underdiagnosed. Its draft cites an estimated prevalence in England of 26.6 per 100,000 people.

The global liver disease treatment market is moderately consolidated, with large drugmakers and specialty biotechs competing through clinical data, approvals, pricing, and access. Madrigal Pharmaceuticals leads in targeted MASH therapy. Novo Nordisk is a strong rival with Wegovy and the Akero deal. Gilead Sciences and AbbVie have a strong presence in hepatitis. GSK, Roche, and Amoytop Biotech are building positions in hepatitis B and MASH.

Competition is shifting toward outcomes data, combination therapy, and payer value. Madrigal's cash and securities stood at US$838.9 million as of June 30, 2026. Novo agreed to add an FGF21 candidate through Akero. Roche and GSK have also made MASH deals. Smaller biotechs focus on niche targets and licensing partnerships. Entry barriers are high, as late-stage trials and regulatory filings need large budgets.

Key Industry Developments

• In October 2026, the U.S. FDA approved Hibsago (bepirovirsen), developed by GSK, for certain adults with chronic hepatitis B without cirrhosis. The first FDA-approved antisense oligonucleotide for chronic hepatitis B is indicated in combination with existing antiviral therapy for eligible patients with suppressed viral DNA and specified hepatitis B surface antigen levels. In the Phase III B-Well trials, 19% of patients receiving bepirovirsen achieved functional cure, compared with none in the placebo group. The approval introduced a treatment approach aimed at allowing some patients to maintain viral control after stopping all hepatitis B medication.
• In July 2026, Ipsen announced positive Phase IIIb results for IQIRVO (elafibranor) in patients with PBC who had moderately elevated alkaline phosphatase levels. The ELSPIRE trial achieved its primary endpoint, with 85% of patients receiving elafibranor achieving alkaline phosphatase normalization at Week 52, compared with 23% in the placebo group. The findings could support broader use of IQIRVO among PBC patients who have less pronounced biochemical abnormalities but continue to require treatment.
• In May 2026, Zydus Therapeutics received Priority Review from the U.S. FDA for its New Drug Application for saroglitazar to treat PBC. The proposed indication covers patients who have an inadequate response to ursodeoxycholic acid or cannot tolerate the existing treatment. In the Phase III EPICS-III trial, 56.7% of patients receiving saroglitazar achieved a biochemical response, compared with 9.8% receiving placebo. The FDA assigned a target action date of November 27, 2026, bringing the candidate closer to a potential U.S. regulatory decision.